Nuvalent (NUVL) Projected to Post Quarterly Earnings on Thursday

Nuvalent (NASDAQ:NUVL - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($1.17) per share for the quarter.

Nuvalent (NASDAQ:NUVL - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($1.03) by ($0.02). On average, analysts expect Nuvalent to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Nuvalent Stock Up 1.6 %

Shares of NUVL traded up $1.23 during mid-day trading on Friday, reaching $77.46. The company's stock had a trading volume of 560,960 shares, compared to its average volume of 477,688. The company has a market cap of $5.55 billion, a price-to-earnings ratio of -22.32 and a beta of 1.43. Nuvalent has a 1 year low of $55.54 and a 1 year high of $113.51. The business has a fifty day moving average of $71.77 and a 200 day moving average of $81.46.

Insider Transactions at Nuvalent

In other Nuvalent news, Director Matthew Shair sold 2,000 shares of the stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $78.43, for a total transaction of $156,860.00. Following the transaction, the director now owns 216,522 shares in the company, valued at $16,981,820.46. This trade represents a 0.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO James Richard Porter sold 27,000 shares of the company's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $75.87, for a total transaction of $2,048,490.00. Following the sale, the chief executive officer now directly owns 249,062 shares of the company's stock, valued at approximately $18,896,333.94. This represents a 9.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 83,000 shares of company stock worth $6,185,150. 12.52% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. HC Wainwright reiterated a "buy" rating and issued a $110.00 target price on shares of Nuvalent in a research report on Monday, March 3rd. Wedbush reiterated an "outperform" rating and set a $115.00 price objective on shares of Nuvalent in a report on Monday, January 13th. Finally, UBS Group upgraded Nuvalent from a "neutral" rating to a "buy" rating and set a $100.00 target price on the stock in a research note on Friday, March 14th. One equities research analyst has rated the stock with a sell rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $115.50.

Nuvalent Company Profile

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.